Pfizer’s vaccine “survives” outside the ultra-cold network | Digital Trends Spanish
Pharmaceutical Pfizer reported to the United States authorities that their messenger RNA vaccine, developed in conjunction with Germany’s BioNTech, remains stable and useful for two weeks if stored at minus 15 degrees Celsius in a conventional medical refrigerator.
These conditions would facilitate the transportation and therefore the application of the Pfizer and BioNTech vaccine – one of the most effective and safe – in thousands of places around the world.
Prior to this announcement, Pfizer asked countries that administer its vaccine to have a network of ultra-cold freezers capable of maintaining temperatures between minus 60 and minus 80 degrees Celsius, approximately minus 112 degrees Fahrenheit.
“We have data that supports the safe handling of the vaccine at minus 20 degrees Celcius, which can facilitate its application in pharmacies by giving vaccination centers greater flexibility,” said BioNTech CEO Ugur Sahin.
In accordance with information published by the Centers for Disease Control and Prevention (CDC), the Pfizer and BioNTech vaccine is 95 percent effective after a two-dose regimen.
The American drugmaker Moderna’s vaccine, which also uses messenger RNA and required ultra-cold freezers, can remain useful for up to six months, the company reported.
“Now we do not need ultra-cold conditions, as the quality of the product has improved and it no longer needs extreme cold to avoid RNA degradation,” said a spokesperson for the pharmaceutical company.